A blood based molecular test might direct recommendations for systemic therapies in early stage breast cancer patients receiving surgery with curative intent. A new study suggests that droplet digital polymerase chain reaction can be used to detect cancer-specific DNA alterations in plasma with sensitivity suitable for monitoring minimal residual disease

Minimal residual disease in breast cancer: in blood veritas.

SIRAVEGNA, GIULIA;BARDELLI, Alberto
2014-01-01

Abstract

A blood based molecular test might direct recommendations for systemic therapies in early stage breast cancer patients receiving surgery with curative intent. A new study suggests that droplet digital polymerase chain reaction can be used to detect cancer-specific DNA alterations in plasma with sensitivity suitable for monitoring minimal residual disease
2014
20
10
2505
2507
Randomized trial; dna; survival
Siravegna G; Bardelli A
File in questo prodotto:
File Dimensione Formato  
POST_2014-Siravegna et al_Minimal_4aperto.pdf

Open Access dal 02/06/2015

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 276.81 kB
Formato Adobe PDF
276.81 kB Adobe PDF Visualizza/Apri
2014-Minimal residual disease.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 410.03 kB
Formato Adobe PDF
410.03 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/152059
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact